Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9

Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia

Authors Saruwatari J, Yasui-Furukori N, Kamihashi R, Yoshimori Y, Oniki K, Tsuchimine S, Noai M, Sato Y, Nakagami T, Sugawara N, Saito M, Fujii A, Kajiwara A, Mihara S, Ogata Y, Kaneko S, Nakagawa K

Received 6 August 2013

Accepted for publication 5 September 2013

Published 1 November 2013 Volume 2013:9 Pages 1683—1698

DOI https://doi.org/10.2147/NDT.S52585

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 6

Junji Saruwatari,1,* Norio Yasui-Furukori,2,* Ryoko Kamihashi,1 Yuki Yoshimori,1 Kentaro Oniki,1 Shoko Tsuchimine,2 Madoka Noai,1 Yasushi Sato,3 Taku Nakagami,4 Norio Sugawara,2 Manabu Saito,2 Akira Fujii,2 Ayami Kajiwara,1 Shuichi Mihara,5 Yasuhiro Ogata,6 Sunao Kaneko,2 Kazuko Nakagawa1,7

1Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, 2Department of Neuropsychiatry, Hirosaki University School of Medicine, Hirosaki, 3Department of Psychiatry, Hirosaki Aiseikai Hospital, Hirosaki, 4Department of Psychiatry, Odate Municipal General Hospital, Odate, 5Mihara Life Care Clinic, Kumamoto, 6Japanese Red Cross Kumamoto Health Care Center, Kumamoto, 7Center for Clinical Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan

*These authors contributed equally to this paper

Background: This study investigated the possible association between common and potentially functional polymorphisms of antioxidant enzymes and metabolic abnormalities in patients with schizophrenia.
Methods: The possible associations of the glutathione S-transferase (GST) M1 null and GSTT1 null genotypes, and the superoxide dismutase 2 (SOD2) Val16Ala polymorphism with the risks of being overweight and having metabolic syndrome were examined using a logistic regression analysis in 154 schizophrenic Japanese patients and 203 controls.
Results: Among smokers with schizophrenia, the risks of being overweight and having decreased high-density lipoprotein cholesterol were significantly higher in those with the GSTM1 null genotype than in those with the present genotype (odds ratio 3.20 and 3.15, P=0.03 and P=0.04, respectively), while among nonsmokers with schizophrenia, the risk of an abnormal waist circumference was lower in those with the GSTM1 null genotype (odds ratio 0.34, P=0.04). The risk of a decreased high-density lipoprotein cholesterol level was significantly higher in patients with the combined GSTM1 null and GSTT1 present genotypes than in those with the present genotypes of both genes (odds ratio 3.60, P<0.01). The SOD2 Val16Ala polymorphism was not associated with risk of metabolic abnormalities in either group.
Conclusion: The present study suggests that the GSTM1 null genotype, in combination with smoking status or GSTT1 genotype, might be associated with the metabolic abnormalities in patients with schizophrenia.

Keywords: schizophrenia, metabolic syndrome, oxidative stress, glutathione S-transferase, superoxide dismutase 2, polymorphism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Possible association between moderate intellectual disability and weight gain in valproic acid–treated patients with epilepsy

Tanamachi Y, Saruwatari J, Noai M, Kamihashi R, Soraoka H, Yoshimori Y, Ogusu N, Oniki K, Yasui-Furukori N, Ishitsu T, Nakagawa K

Neuropsychiatric Disease and Treatment 2015, 11:1007-1014

Published Date: 7 April 2015

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N

Pharmacogenomics and Personalized Medicine 2014, 7:121-127

Published Date: 28 April 2014

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010